Discover
BLLN
BillionToOne, Inc.
122.33
2 x 89.77
1 x 153.36
bid
ask
+
2.35
1.96%
2 @ 04:00 PM
124.53 +2.20 (1.80%)
| Ytd | 49.47% | |
| 1y | 12.29% |
119.50
day range
124.94
61.96
52 week range
138.70
| Open | 121.26 | Prev Close | 119.98 | Low | 119.50 | High | 124.94 | Mkt Cap | 5.63B |
| Vol | 687.68K | Avg Vol | 680.59K | EPS | 0.54 | P/E | 226.54 | Forward P/E | 118.77 |
| Beta | N/A | Short Ratio | 2.40 | Inst. Own | 37.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 94.10 | 200-d Avg | 90.31 | 1yr Est | 117.71 |
BLLN News
gurufocus.com
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-o
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-o
prnewswire.com
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-o
Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor type
benzinga.com
Guggenheim Initiates Coverage On BillionToOne with Buy Rating, Raises Price Target to $125
Guggenheim analyst Subbu Nambi initiates coverage on BillionToOne (NASDAQ:BLLN) with a Buy rating